-
Mashup Score: 0OncLive® ASH 2023 On Location - 6 month(s) ago
AdvertisementOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference.Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0OncLive® ASH 2023 On Location - 6 month(s) ago
AdvertisementOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference.Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Register today: OncLive® News Network: On Location at the 2023 American Society of Hematology Annual Meeting! Join us for 3 days of exclusive interviews with top thought leaders: https://t.co/do2mqFZCMJ https://t.co/VukACSiTrL
-
-
Mashup Score: 0OncLive® ASH 2023 On Location - 6 month(s) ago
AdvertisementOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference.Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Register today: OncLive® News Network: On Location at the 2023 American Society of Hematology Annual Meeting! Join us for 3 days of exclusive interviews with top thought leaders: https://t.co/do2mqFZCMJ https://t.co/VukACSiTrL
-
-
Mashup Score: 0
Complete the registration form below to join our upcoming broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance.10/26/2023, 7:00 PM ET10/26/2023, 9:00 PM ETRegister to secure your time slot.Already registered? Login here.Program ObjectivesReview the unmet needs for patients with…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance https://t.co/DKT58WLvFu https://t.co/M6xdtLEIWT
-
-
Mashup Score: 1OncLive® ESMO 2023 On Location - 7 month(s) ago
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference. Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
ICYMI: This episode of #OncLiveOnLocation is available to watch now! Hear what @tompowles1 had to say LIVE at @myESMO on updates from the meeting and the latest to come out of GU Cancers! https://t.co/c6gjvYuKNU https://t.co/10dC9YhEKi
-
-
Mashup Score: 0OncLive® ESMO 2023 On Location - 7 month(s) ago
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference. Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
ICYMI: This episode of #OncLiveOnLocation is available to watch now! Hear what @tompowles1 had to say LIVE at @myESMO on updates from the meeting and the latest to come out of GU Cancers! https://t.co/c6gjvYuKNU https://t.co/10dC9YhEKi
-
-
Mashup Score: 0
Complete the registration form below to join our upcoming broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance.10/26/2023, 7:00 PM ET10/26/2023, 9:00 PM ETRegister to secure your time slot.Already registered? Login here.Program ObjectivesReview the unmet needs for patients with…
Source: studio.mjhassoc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join our upcoming broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance https://t.co/DKT58WLvFu https://t.co/2emHmzl2yf
-
-
Mashup Score: 0OncLive® ESMO 2023 On Location - 8 month(s) ago
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference. Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Register for OncLive® On Location: live from the 2023 ESMO Congress! Hear exclusive interviews at 6 PM ET on October 20-22. Register here to secure your seat: https://t.co/16XP6AvjWG https://t.co/IeECL94V6Q
-
-
Mashup Score: 1
Complete the registration form below to join our upcoming broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance.10/26/2023, 7:00 PM ET10/26/2023, 9:00 PM ETRegister to secure your time slot.Already registered? Login here.Program ObjectivesReview the unmet needs for patients with…
Source: studio.mjhassoc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join our upcoming broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance https://t.co/DKT58WLvFu https://t.co/1Qo6DRVwMR
-
-
Mashup Score: 0BTK Inhibition for Adult Patients with CLL or SLL: An Overview of MOA, Clinical Data, and Dosing Considerations - 8 month(s) ago
HemorrhageFatal and serious hemorrhage has occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher hemorrhage, including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 3.6% of patients treated with BRUKINSA monotherapy in clinical trials, with fatalities occurring in 0.3% of patients. Bleeding of any…
Source: studio.mjhassoc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join our upcoming National Broadcast with Live Q&A – BTK Inhibition for Adult Patients with CLL or SLL: An Overview of MOA, Clinical Data, and Dosing Considerations. https://t.co/sVhSKR1Iat https://t.co/NBg56kwGRy
-
Register today: OncLive® News Network: On Location at the 2023 American Society of Hematology Annual Meeting! Join us for 3 days of exclusive interviews with top thought leaders: https://t.co/do2mqFZCMJ https://t.co/VukACSiTrL